Bio-Techne Corp stock has seen significant activity, with organizations such as Teacher Retirement System of Texas, Norges Bank, and BI Asset Management Fondsmaeglerselskab A S adjusting their positions. Principal Financial Group Inc, and Assenagon Asset Management S.A. however, have reduced their holdings. Bio-Techne's Q2 and Q3 2024 earnings reports reflect mixed results amidst market challenges. Despite some financial analysts downgrading the company to neutral due to valuations, the intrinsic value of Bio-Techne shares is predicted to be 25-32% higher than their present rate.
Amid several prominent organizational changes, Bio-Techne announced the appointment of Kim Kelderman as CEO and Matthew F. McManus as President of Diagnostics. The Corporation also received European IVDR certification for a diagnostic test monitoring chronic conditions and announced a new distribution agreement with Thermo Fisher Scientific. Bio-Techne continues to present at multiple healthcare conferences and has filed a patent infringement lawsuit against Molecular Instruments. Furthermore, they recently completed their investment in Wilson Wolf Manufacturing, providing further evidence of assertive growth strategies.
Bio-Techne Corp TECH News Analytics from Tue, 14 Feb 2023 08:00:00 GMT to Sun, 26 May 2024 14:02:53 GMT - Rating 7 - Innovation 8 - Information 8 - Rumor 5
